This recognition of quality is a step forward in the company's internationalisation process. In 2017 it hopes to move into markets such as the United Kingdom and Italy.
Judit Amposta: “It is the first specialist swine model CRO in Europe with GLP and offers services from breeding to pre-clinical trials of drugs and healthcare devices”
Specipig has obtained a certificate of compliance with the principles of Good Laboratory Practices (GLP) from the Department of Health (Government of Catalonia) for conducting trials of toxicity, tolerance and biocompatibility in drugs for human use and healthcare devices.
This certification has been awarded as the result of implementing a wider quality assurance system, allowing the company to position itself "as the first Contract Research Organisation in Europe specialising in the swine model and GLP certified, offering services ranging from breeding of the animal model to preclinical CRO services” explained Judit Amposta, Specipig’s Director of Quality Assurance Unit. Amposta is an expert in creating and implementing new quality systems in the pharmaceutical and biotechnology sector and has worked as technical and quality assurance director in various laboratories and companies in the sector. She also jointly coordinates the postgraduate degree in Quality Systems for Industry and Pharmaceutical Research at the University of Barcelona.
One of Specipig’s targets for 2017 is to boost the internationalisation of its CRO services. The GLP certification opens up the possibility of working with companies from around the world to support the development of its products from the earliest stages by conducting efficiency tests on new drugs and validating medical devices right up to regulatory trials of toxicity, tolerance and biocompatibility.
Specipig also plans to set up a new operating theatre this year.